Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1989 1
1992 1
1994 2
1995 1
1996 1
1998 2
1999 5
2000 1
2001 8
2002 1
2003 2
2004 4
2005 2
2006 1
2007 3
2008 1
2010 2
2012 4
2013 1
2014 1
2015 1
2016 1
2017 3
2018 3
2019 2
2020 3
2021 3
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Zatreanu D, Robinson HMR, Alkhatib O, Boursier M, Finch H, Geo L, Grande D, Grinkevich V, Heald RA, Langdon S, Majithiya J, McWhirter C, Martin NMB, Moore S, Neves J, Rajendra E, Ranzani M, Schaedler T, Stockley M, Wiggins K, Brough R, Sridhar S, Gulati A, Shao N, Badder LM, Novo D, Knight EG, Marlow R, Haider S, Callen E, Hewitt G, Schimmel J, Prevo R, Alli C, Ferdinand A, Bell C, Blencowe P, Bot C, Calder M, Charles M, Curry J, Ekwuru T, Ewings K, Krajewski W, MacDonald E, McCarron H, Pang L, Pedder C, Rigoreau L, Swarbrick M, Wheatley E, Willis S, Wong AC, Nussenzweig A, Tijsterman M, Tutt A, Boulton SJ, Higgins GS, Pettitt SJ, Smith GCM, Lord CJ. Zatreanu D, et al. Among authors: prevo r. Nat Commun. 2021 Jun 17;12(1):3636. doi: 10.1038/s41467-021-23463-8. Nat Commun. 2021. PMID: 34140467 Free PMC article.
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models.
Rodriguez-Berriguete G, Ranzani M, Prevo R, Puliyadi R, Machado N, Bolland HR, Millar V, Ebner D, Boursier M, Cerutti A, Cicconi A, Galbiati A, Grande D, Grinkevich V, Majithiya JB, Piscitello D, Rajendra E, Stockley ML, Boulton SJ, Hammond EM, Heald RA, Smith GCM, Robinson HMR, Higgins GS. Rodriguez-Berriguete G, et al. Among authors: prevo r. Clin Cancer Res. 2023 Apr 14;29(8):1631-1642. doi: 10.1158/1078-0432.CCR-22-2977. Clin Cancer Res. 2023. PMID: 36689546 Free PMC article.
Targeting ATR in DNA damage response and cancer therapeutics.
Fokas E, Prevo R, Hammond EM, Brunner TB, McKenna WG, Muschel RJ. Fokas E, et al. Among authors: prevo r. Cancer Treat Rev. 2014 Feb;40(1):109-17. doi: 10.1016/j.ctrv.2013.03.002. Epub 2013 Apr 11. Cancer Treat Rev. 2014. PMID: 23583268 Review.
LYVE-1, the lymphatic system and tumor lymphangiogenesis.
Jackson DG, Prevo R, Clasper S, Banerji S. Jackson DG, et al. Among authors: prevo r. Trends Immunol. 2001 Jun;22(6):317-21. doi: 10.1016/s1471-4906(01)01936-6. Trends Immunol. 2001. PMID: 11377291 Review.
Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer.
Skwarski M, McGowan DR, Belcher E, Di Chiara F, Stavroulias D, McCole M, Derham JL, Chu KY, Teoh E, Chauhan J, O'Reilly D, Harris BHL, Macklin PS, Bull JA, Green M, Rodriguez-Berriguete G, Prevo R, Folkes LK, Campo L, Ferencz P, Croal PL, Flight H, Qi C, Holmes J, O'Connor JPB, Gleeson FV, McKenna WG, Harris AL, Bulte D, Buffa FM, Macpherson RE, Higgins GS. Skwarski M, et al. Among authors: prevo r. Clin Cancer Res. 2021 May 1;27(9):2459-2469. doi: 10.1158/1078-0432.CCR-20-4128. Epub 2021 Feb 17. Clin Cancer Res. 2021. PMID: 33597271 Free PMC article.
59 results